Reduce Crohn's-Associated Diarrhea With Sodium Channel Therapy

Phase 2

Terminated

Conditions: Inflammatory Bowel Disease
Crohn's Disease

Interventions: Drug: Ranolazine
Drug: Placebo

Registration Number: NCT04456517

Lead Sponsor: Vanderbilt University Medical Center

Brief Summary: Crohn's disease is an inflammatory disorder that can affect any part of the gastrointestinal (GI) tract. Some patients still experience persistent diarrhea or other symptoms such as abdominal pain even when their Crohn's disease is in remission. Diarrhea and/or abdominal pain that is not responsive to standard therapies can significantly affect a patient's quality of life and ability to work. The purpose of this study is to test the safety and effectiveness of the drug ranolazine in reducing Crohn's disease-associated diarrhea and other symptoms. Ranolazine is approved by the US Food \& Drug Administration (FDA) for chronic angina (a heart condition). This study is investigating if ranolazine could be used in the setting of Crohn's disease.

Detailed Description: Not available

Recruitment & Eligibility

Status: TERMINATED

Sex: All

Target Recruitment: 4

Inclusion Criteria

Meet diagnostic criteria for Crohn's Disease with active diarrhea Either with active disease or in remission (as defined by endoscopic or radiographic findings) but experiencing symptoms (e.g., diarrhea, abdominal pain)
Have greater than three loose stools per day

Exclusion Criteria

Male and female subjects <18 years of age
Significant change in medication including prednisone, antidepressant medications, or stimulants within the last 4 weeks

a. Allowances include: Rectal hydrocortisone, rectal mesalamine, addition of prednisone (up to 20mg) for flares, etc.
Regular (daily) use of opioids or other drugs of abuse including heavy alcohol or marijuana use
Severe psychiatric disease including schizophrenia, psychosis, suicidal depression
Previous use of ranolazine within 2 months prior to enrollment
Prior use of ranolazine which was discontinued for safety or tolerability
Metabolic derangement defined as liver function tests >3x upper limit of normal or severe renal disease defined as calculated creatinine clearance <30 mL/min
Have liver cirrhosis
Concurrent use of CYP3A inhibitors, inducers, or substrates

a. These may include: ketoconazole, itraconazole, nefazodone, nelfinavir, ritonavir, indinavir, and saquinavir, clarithromycin, or rifampin, rifapentine, phenobarbital, phenytoin, and St. John's Wort, digoxin.
A family history of (or congenital) long QT syndrome or known acquired QT interval prolongation
Inability or refusal to give informed consent for any reason including a diagnosis of dementia or cognitive impairment
Patients who are pregnant or breastfeeding
Patients who are enrolled in other investigational drug studies or who have taken investigational drugs within 30 days before enrollment
Other factors which in the opinion of the investigator could potentially impact the study outcomes (e.g., underlying disease, medications, history) or prevent the participant from completing the protocol (poor compliance or unpredictable schedule)

Study & Design

Study Type: INTERVENTIONAL

Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
Ranolazine, Then Placebo	Ranolazine	- Participants first receive a Ranolazine 500 mg tablet twice daily for 12 weeks, they then receive a Placebo tablet (matching Ranolazine 500 mg tablets) twice daily for 12 weeks. This treatment will be given to participants with either active CD or patients with CD that is in remission but who experience continued symptoms
Ranolazine, Then Placebo	Placebo	- Participants first receive a Ranolazine 500 mg tablet twice daily for 12 weeks, they then receive a Placebo tablet (matching Ranolazine 500 mg tablets) twice daily for 12 weeks. This treatment will be given to participants with either active CD or patients with CD that is in remission but who experience continued symptoms
Placebo, Then Ranolazine	Placebo	- Participants first receive a Placebo tablet (matching Ranolazine 500 mg tablets) twice daily for 12 weeks, they then receive a Ranolazine 500mg tablet twice daily for 12 weeks. This treatment will be given to participants with either active CD or patients with CD that is in remission but who experience continued symptoms
Placebo, Then Ranolazine	Ranolazine	- Participants first receive a Placebo tablet (matching Ranolazine 500 mg tablets) twice daily for 12 weeks, they then receive a Ranolazine 500mg tablet twice daily for 12 weeks. This treatment will be given to participants with either active CD or patients with CD that is in remission but who experience continued symptoms

Primary Outcome Measures

Name	Time	Method
Daily Number of Loose Stools	Baseline to 12 weeks	Daily number of loose stools will be collected directly from all subjects using MyCap.

Secondary Outcome Measures

Name	Time	Method
Crohn's Disease Activity Index (CDAI) Score	Baseline to 12 weeks	The Crohn's Disease Activity Index (CDAI) combines weighted scores of clinical and laboratory variables to estimate disease severity. The CDAI consists of eight variables, two of which are subjective, related to the disease, each weighted according to its ability to be predictive of disease activity. The absolute score ranges from 0 to 600. CDAI scores of less than 150 indicate a clinical remission and scores over 450 indicate severely active disease. Since blood draws will not be performed as part of this study, the hematocrit component of the CDAI will not be assessed.
Harvey Bradshaw Index (HBI) Score	Baseline to Week 12	The Harvey-Bradshaw index (Harvey-Bradshaw Index - HBI) assesses the degree of illness (activity) in patients with Crohn's disease. The HBI consists of 5 items with a minimum score of 0 and a maximum attainable score depending on the number of stools the patient identifies per day. HBI scores \< 5 are defined as clinical remission, HBI between 5 and 7 as mild disease, HBI between 8 and 16 as moderate disease, and HBI \> 16 as severe disease.
Short Inflammatory Bowel Disease Questionnaire (SIBDQ) Score	Baseline to 12 weeks	The SIBDQ is a 10-item questionnaire measuring quality of life in four domains: bowel symptoms, emotional health, systemic symptoms, and social function and is scored on a 7-point Likert scale from 1 (severe problem) to 7 (no problems at all). The absolute score ranges are from 10 (poor Health-related quality of life) to 70 (optimum Health-related quality of life).
Patient Health Questionnaire (PHQ-9) Score	Baseline to week 12	The PHQ-9 is a 9-item questionnaire that screens for the presence and severity of depression and can be used to make a depression diagnosis using DSM-IV criteria. The PHQ-9 is scored on a 3-point Likert scale from 0 (not at all) to 3 (nearly every day). The absolute score ranges are from 0 (none or minimal depression) to 27 (severe depression).